Genelux (NASDAQ:GNLX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLX) from a strong sell rating to a sell rating in a report issued on Sunday morning.

GNLX has been the topic of several other research reports. Benchmark reissued a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Genelux Stock Performance

Shares of GNLX opened at $2.72 on Friday. The firm has a market capitalization of $123.05 million, a PE ratio of -3.16 and a beta of 0.60. The stock has a 50 day simple moving average of $2.85 and a 200 day simple moving average of $2.77. Genelux has a 52-week low of $2.29 and a 52-week high of $8.53.

Genelux (NASDAQ:GNLX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Equities research analysts predict that Genelux will post -0.81 EPS for the current fiscal year.

Insider Transactions at Genelux

In other Genelux news, Director John W. Smither sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total transaction of $34,920.00. Following the transaction, the director owned 91,403 shares of the company’s stock, valued at $265,982.73. The trade was a 11.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Thomas sold 10,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $2.98, for a total transaction of $29,800.00. Following the completion of the transaction, the director directly owned 472,784 shares in the company, valued at $1,408,896.32. The trade was a 2.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,868 shares of company stock valued at $76,120 in the last quarter. 7.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Genelux

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. acquired a new stake in shares of Genelux during the 4th quarter worth $48,000. GSA Capital Partners LLP bought a new stake in Genelux during the second quarter worth about $35,000. Squarepoint Ops LLC bought a new position in Genelux in the 4th quarter valued at about $52,000. Balyasny Asset Management L.P. bought a new position in Genelux in the 4th quarter valued at about $94,000. Finally, Align Financial LLC acquired a new position in shares of Genelux in the 4th quarter valued at approximately $123,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.